Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named KEYNOTE-427, showed a favorable safety profile, similar to that established in other trials focused on other tumor types. In this study, pembrolizumab was used as first line treatment with overall recovery rates (ORR) of 38%.

Learn more by clicking here.